RARITAN, NJ, October 20, 2014 - Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) to the U.S. Food ...

Pennsylvanians will see their out-of-pocket costs for 10 medications drop by 53% on average, according to a new AARP report.

Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed. Imbruvica (ibrutinib ...

Savings for Part D and Advantage enrollees depend largely on which plan they’re enrolled in, as not all plans are the same.

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p ...

R-MPV plus Imbruvica achieved a 97% complete response rate in newly diagnosed PCNSL patients, with a 100% overall response rate and no refractory cases. The two-year progression-free survival rate was ...

(Reuters) - Johnson and Johnson said on Tuesday a combination therapy containing its blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs ...

There’s good news in 2026 for seniors enrolled in Medicare Part D who rely on the priciest prescription drugs: 10 high-cost ...

Janssen Biotech and Pharmacyclics withdrew a proposed plan to introduce a new version of their blood cancer drug Imbruvica at triple the cost of the original, reports The Washington Post. At present, ...

Johnson & Johnson’s (NYSE: JNJ) Imbruvica is poised to beat Roche’s top selling drug in the chronic lymphocytic leukemia drugs market over the next few years. This can be attributed to expected ...